Bihua Chen

October 16, 2026

BBOT reports inducement grants under Nasdaq Rule 5635(c)(4). BridgeBio Oncology Therapeutics announced that it has reported inducement grants in accordance with Nasdaq Listing Rule 5635(c)(4). The disclosure confirms the company’s compliance with regulatory reporting requirements for incentive arrangements. While the announcement does not provide details on the size of the grants, it highlights ongoing governance practices.

September 25, 2026

MLTX noted in psoriatic arthritis market landscape report. A recent DelveInsight analysis outlined six late‑stage drugs expected to drive growth in the psoriatic arthritis market. The report highlights the expanding opportunity for immunotherapy developers, which includes companies such as MoonLake Immunotherapeutics. This broader market view may influence how investors view MLTX's pipeline prospects.

September 29, 2026

Biomea Fusion Cancels Equity Offering, Shares Drop 19%. Biomea Fusion announced the termination of its proposed public equity offering, citing market conditions. The cancellation removes expected dilution relief and leaves the company with near‑term runway pressure. Following the news, the stock fell about 19% in after‑hours trading. The development occurs amid broader health‑care stock activity.

October 8, 2026

Erasca Faces Verastem Competition Amid Clinical Updates. Recent analysis highlights that Verastem's upcoming clinical data and commercial launch present a competitive challenge for Erasca. While Erasca's Revolution approval has reduced some development risk, the market is watching how the company navigates this new competitive landscape. The stock currently trades near significant support levels, reflecting cautious sentiment as investors assess these developments.